Synthesis 2017; 49(10): 2266-2274
DOI: 10.1055/s-0036-1588130
paper
© Georg Thieme Verlag Stuttgart · New York

Development of an Industrial Process Based on the Groebke–Blackburn–Bienaymé Multicomponent Reaction: Efficient Preparation­ of 3-Aminoimidazo[1,2-a]pyrazines

Markus Baenziger
,
Estelle Durantie*
,
Christian Mathes
Further Information

Publication History

Received: 18 November 2016

Accepted after revision: 06 December 2016

Publication Date:
31 January 2017 (online)

 


Abstract

3-Aminoimidazo[1,2-a]pyrazine is an important scaffold that is found in many drugs. This scaffold is rapidly accessible through a Groebke–Blackburn–Bienaymé cyclisation starting from an aminopyrazine, an aldehyde and an isocyanide. A scale-up process of this multicomponent reaction has been achieved in high yield and with excellent purity. The scope and limitations of this process leading to various 3-aminoimidazo[1,2-a]pyrazines are disclosed.


#

3-Aminoimidazo[1,2-a]pyrazines are important building blocks for the pharmaceutical and agrochemical industries. These compounds are accessible through the three-component Groebke–Blackburn–Bienaymé cyclisation (GBB reaction) involving an aldehyde, an amine (or preformed imine) and an isonitrile. This multicomponent reaction (MCR) was discovered independently by three pharmaceutical groups at Hoffmann La Roche (Groebke),[2] Millenium Pharmaceutical (Blackburn)[3] and Rhone Poulenc (Bienaymé)[4] in 1998. Recently, it became attractive to the scientific community, especially to pharmaceutical research groups, because a broad variety of target compounds can be made by varying the three compounds, leading to combinatorial libraries.[5]

For our development activities, we required an efficient and scalable synthesis of aminoimidazopyrazine derivatives 1a (Scheme [1]) and 1b (Table [2]), which are key intermediates for drug candidates designed to treat malaria.[6] In this manuscript, we report on our progress toward the development of a practical process for the synthesis of intermediate 1b by using the GBB reaction from easily accessible starting materials: 2-aminopyrazine, 4-fluorobenzaldehyde and 1,2-difluoro-4-isocyanobenzene. We have examined the impact of dehydrating agents, Lewis acids and isocyanide quantity on this three-component reaction. We also studied the scope and limitations of this GBB reaction for various aldehydes and isocyanides and have established optimised reaction conditions.

Our objective was to develop a one-pot process that was suitable for manufacturing 3-aminoimidazo[1,2-a]pyrazine 1 on an industrial scale. Preliminary investigations of the MCR was performed utilising the reaction conditions shown in Scheme [1], in which 2-aminopyrazine (2), benzaldehyde (3a) and isocyanide 4a reacted in the presence of boron trifluoride and a catalytic amount of p-toluene sulfonic acid (PTSA). Under these conditions, the reaction rate appeared to be very slow, as indicated by gas chromatography analyses. After three days, only 49% conversion was observed.

Zoom Image
Scheme 1 Toward a one-pot process. Reagents and conditions: 2 (1 equiv), 3a (1 equiv), 4a (1 equiv), PTSA (1.2 mol%), BF3·MeCN (4 mol%), r.t., CH2Cl2.

Although the GBB reaction can be effective in water at elevated temperature,[7] we thought that the water by-product formed during the reaction could slow down the conversion into product 1. To test this hypothesis, we added a dehydrating agent to the previous reaction, which greatly increased its rate (Table [1]). GC analyses of the crude reaction mixture after 17 hours showed that the conversion was increased from 40% to 64 and 86% by adding MgSO4 and trimethyl orthoformate, respectively (entries 2 and 3). The use of trimethyl orthoformate as dehydrating agent led to a homogeneous reaction mixture, which is more appropriate for industrial processes. Furthermore, unreacted trimethyl orthoformate can be easily separated from the product by evaporation. Product 1a was isolated as a sulfate salt by filtration in 44% yield. Formation of the sulfate salt was found to be a scalable purification method, which avoided time-consuming and cost-demanding processes such as column chromatographic purification. The sulfate salt was prepared by adding sulfuric acid to crude 1a in isopropanol and isolated by simple filtration in good purity.

Table 1 Effect of Dehydrating Agent

Entry

Dehydrating agent

Yield (%)a

1

none

40

2

MgSO4 (2 equiv)

64

3

trimethyl orthoformate (2 equiv)

80

a Yield based on GC analyses of the crude reaction mixture after 17 h.

The impact of isocyanide stoichiometry on the GBB reaction was then investigated (Table [2]). The preformed imine 5b was treated with 0.8 to 5 equivalents of isocyanide. The highest yield was obtained when 3 equivalents of isocyanide were used (entry 3). Surprisingly, increasing the amount of isocyanide from 3 to 5 equivalents decreased the isolated yield (entry 4). GC analyses of the isolated 1b sulfate salt revealed that the more isocyanide added, the lower the purity obtained (entries 2 and 3). Supported by 1H NMR analysis of the isolated salt, the major impurity appeared to be a side-product derived from the isocyanide. It could be formed during the reaction or from the prepared isocyanide solution. This point will be discussed later.

Table 2 Stoichiometry of Isocyanidea

Entry

Equivalent

Yield (%)b

Purity (%)c

1

0.8

35

 71

2

1

43

>99

3

3

89

 90

4

5

68

 77

a Reaction conditions: BF3·MeCN (5 mol%), trimethyl orthoformate (2 equiv), CH2Cl2, r.t., 3 days.

b Isolated yield of the corresponding sulfate salt.

c Purity based on GC analyses.

Furthermore, the impact of Lewis acids was examined. Imine 5b was treated with isocyanide 4b in the presence of a variety of Lewis acids as shown in Table [3]. Titanium tetrachloride and aluminium chloride furnished the desired product 1b in high yields of 83 and 89%, respectively (entries 3 and 4). In terms of purity, the reaction with boron trifluoride-acetonitrile complex appeared to be more attractive. The reaction provided 1b with excellent purity (>99%) and in moderate yield (63%).

Table 3 Influence of the Lewis Acid in the GBB Reaction Leading to 1b a

Entry

Lewis acid

Yield (%)b

Purity (%)c

1

BF3·MeCN

63

>99

2

ZnCl2 d

64

 84

3

TiCl4

83

 81

4

AlCl3

89

 79

5

Ti(iPrO)4

10

 37

6

I2

84

 74

7

TMSCle

77

 74

a Reaction conditions: 5b (1 equiv), 4b (3 equiv), BF3·MeCN (5 mol%), trimethyl orthoformate (2 equiv), CH2Cl2, r.t., 3 days.

b Isolated yield of the corresponding sulfate salt.

c Purity determined by GC analyses.

d 0.25 equiv Lewis acid.

e 1 equiv Lewis acid.

We previously pointed out that the quality of isocyanides determines the level of impurities observed in the final product. Isocyanides possess some specific features and can be characterised by their repulsive odour and volatility. They are usually sensitive to acid and hydrolyzed to their corresponding formamide when exposed to aqueous acidic conditions. They also have the property to form a complex catalysed by a Lewis acid.[8] Such characteristics need to be taken into account for the preparation of isocyanides. Several methods for the preparation of isocyanides are known and have been well described.

Zoom Image
Scheme 2 Preparation of isocyanide
Zoom Image
Scheme 3 A scalable one-pot process. Isolated yield of the corresponding salt.
Zoom Image
Scheme 4 Proposed mechanism

Commonly, such compounds are prepared by using the carbylamines method (Hofmann isonitrile synthesis)[9] [10] or by formamide dehydration[11,12] (Scheme [2]). The isocyanides used in the previous reactions were prepared by reaction of the corresponding aniline with dihalocarbene (Scheme [2,] A). In this reaction the dihalocarbene was generated in situ from potassium hydroxide and chloroform. Nucleophilic attack by the aniline and subsequent elimination of 2 equivalents of HCl gave the isocyanide. This method had several disadvantages. First, the reaction did not proceed to full conversion and the remaining aniline could disturb the GBB reaction. An acidic work-up to eliminate this aniline was not feasible because of the instability of isocyanides under such conditions. Furthermore, allowing the reaction to heat, even at lower temperature, could be problematic. Indeed, it has been observed that 1,2-difluorophenyl isocyanide decomposed at 40 °C. Another common way to prepare isocyanide is to dehydrate a formamide (Scheme [2,] B). The formamide was prepared under mild conditions by treating the aniline with methyl formate in the presence of NaHMDS at 0 °C.[13] Among several dehydrating conditions used to obtain isocyanides from formamides, phosphoryl chloride appeared to be the most efficient.[11] [12] The reaction was performed at 0 °C and rapidly completed after 1 hour. Moreover, the diisopropylamine hydrochloric salt formed during the reaction precipitated out from the toluene solution and could easily be eliminated by filtration. The remaining traces of diisopropylamine were removed with a very mild acidic workup.

Employing the optimization conditions for the GBB reaction, two one-pot reactions were carried out (Scheme [3]). First, aminopyrazine, benzaldehyde and prepared isocyanide solution from formamide were combined in toluene in the presence of PTSA (1 mol%), boron trifluoride acetonitrile complex (5 mol%) and trimethyl orthoformate (2 equiv). After one day at r.t., the sulfate salt of 1b was isolated in a satisfactory yield of 61% with excellent purity (>99% determined by GC analysis). The yield was improved when the imine intermediate was pre-formed (Scheme [3], bottom). In this one-pot, two-step process, aminopyrazine, benzaldehyde and p-toluene sulfonic acid (1 mol%) were allowed to heat to reflux with a Dean–Stark apparatus for 16 hours. The isocyanide solution, trimethyl orthoformate and boron trifluoride acetonitrile complex (5 mol%) were then added at room temperature. After stirring for an additional 16 hours, 1b was isolated as a sulfate salt in 85% yield. Scale-up of the reaction (100 mmol) provided 36 grams of 1b in 82% yield. The last result demonstrated the reproducibility and viability of the process on large scale.

The reaction of imine 5b with isonitrile 4b to form product 1b was followed by FTIR measurements. After the addition of isonitrile, the formation of the desired product 1b increases inversely to the consumption of imine 5b, whereas the isonitrile is consumed faster. Interestingly, the rate of formation of the product or consumption of starting materials is very slow during the 25 min after isonitrile addition to the reaction mixture, then it becomes faster. Finally, the rate of formation/consumption of 1b and 5b decreases to approach a plateau after 3.5 hours, while isonitrile is almost completely consumed after 2.5 hours. After about 5 hours, the reaction comes to an end. The rapid consumption of trimethyl orthoformate as soon as isonitrile is added is also notable. The results of this FTIR investigation are summarised in the Supporting Information.

A plausible mechanism for this three-component reaction is depicted in (Scheme [4]). Condensation of aminopyrazine with benzaldehyde affords the imine intermediate after releasing water. The resulting imine is complexed with the Lewis acid boron trifluoride to form iminium species I. Isocyanide addition to iminium I furnishes nitrilium intermediate II. Intramolecular addition of the pyrazine nitrogen to the nitrilium carbon gave intermediate III through 5-exo-dig cyclisation. Aromatisation of III through a 1,3-H shift leads to imidazo[1,2-a]heteroaromatic 1.

Table 4 Investigation of the Isocyaniydea

Entry

RNC

Product

Yield (%)b

1

1b

85

2

1c

70

3

1d

75

4

1e

77

5

1f

78

6

1g

68

 7

1h

62

 8

1i

90

 9

1j

66

10

1k

87

11

1l

70

12

1m

77c

a Reaction conditions: 1. 2 (1 equiv), 3b (1 equiv), PTSA (1 mol%), toluene, reflux, 16 h; 2. R-NC (1.3 equiv), BF3·MeCN (5 mol%), trimethyl orthoformate (2 equiv), CH2Cl2, r.t., 24 h.

b Isolated yield of sulfate salt.

c Yield determined by 1H NMR spectroscopic analysis.

Employing the optimised conditions, the scope and limitations of this GBB process were studied. A variety of isocyanides, aromatic, aliphatic, or functionalised, were investigated (Table [4]). Electron-poor aryl isocyanides (entries 1–6) furnished products 1 in high yield (68–85%). Electron-rich p-methoxyphenyl isocyanide (entry 8) afforded product 1i in an excellent yield of 90%. Both aliphatic and functionalised isocyanides also proceeded in good yields (66–87%; entries 9–12). These results demonstrated the good tolerance of the GBB reaction toward isocyanides.

Various aldehydes were also explored (Table [5]). Reactions for both electron-poor and electron-rich benzaldehydes and 3,4-difluorophenyl isocyanide 4b provided 1s in high yields (82–95%; entries 1–5). When both isocyanide and aldehyde are electron-rich, the yield was lower. For instance, the reaction for p-methoxyphenyl isocyanide and p-methoxybenzaldehyde afforded product 1s in 37% yield determined by 1H NMR spectroscopic analysis of the crude, result not shown. In comparison, the reaction for p-meth­oxyphenyl isocyanide and electron-poor 4-fluorobenzaldehyde gave 1i in an excellent yield of 90% (Table [4], entry 8). Reaction of a heteroaromatic aldehyde, such as pyridine aldehyde, resulted in only 9% conversion (entry 6). Reaction of cyclohexanecarboxaldehyde and 3,4-difluorophenyl isocyanide furnished 1s in 36% (entry 7). No conversion was observed when both isocyanide and aldehyde were aliphatic (entry 8).

To further broaden the scope of this GBB process, we replaced 2-aminopyrazine with 2-aminopyridine 6 (Scheme [5]). Reaction of 6 with fluorobenzaldehyde 3b and difluorophenylisocyanide 4b gave imidazo[1,2-a]pyridine 7 in a good yield of 67%. Encouraged by this promising result, we are currently investigating other scaffolds that we want to disclose in a future manuscript.

Zoom Image
Scheme 5 Preliminary result for the formation of 3-aminoimidazo[1,2-a]pyridine. Reagents and conditions: 1. 6 (1 equiv), 3b (1 equiv), PTSA (1 mol%), toluene, reflux, 16 h; 2. 4b (1.3 equiv), BF3 _MeCN (5 mol%), trimethyl orthoformate (2 equiv), CH2Cl2, r.t., 24 h.

Table 5 Investigation of the Aldehydesa

Entry

R1NC

R2CHO

Product

Yield (%)b

1

4b

1b

85

2

1n

86

3

1o

95

4

1p

84

5

1q

82

6

1r

9c

7

1s

36c

8

1u

n.r.d

a Reaction conditions: 1. 2 (1 equiv), R2-CHO (1 equiv), PTSA (1 mol%), toluene, reflux, 16 h; 2. R1-NC (1.3 equiv), BF3·MeCN (5 mol%), trimethyl orthoformate (2 equiv), CH2Cl2, r.t., 24 h.

b Isolated yield of the sulfate salt.

c Conversion determined by GC analysis of the reaction mixture.

d No reaction.

In conclusion, a scalable process employing a one-pot, three-component, Groebke–Blackburn–Bienaymé type reaction was developed for the syntheses of 3-aminoimidazo[1,2-a]pyrazines in high yield with excellent purity. It was demonstrated that both Lewis acid boron trifluoride and dehydrating agent trimethyl orthoformate were essential to promote this reaction leading to higher yields. The optimised process required no halogenated solvents or heterogeneous conditions. Most products could be isolated and purified by forming their corresponding sulfate salts. Furthermore, this GBB type of reaction has been shown to be versatile with respect to a range of isocyanides and aldehydes, and can be used to synthesise a large pool of valuable 3-aminoimidazo[1,2-a]pyrazines.

The solvents used were bulk quality, used in our scale-up facilities. The starting materials used were purchased from commercial sources (Sigma Aldrich; ABCR). The reactions described in this manuscript were performed in standard laboratory glassware. The NMR spectra were recorded on a Bruker Avance 400 (1H NMR: 400 MHz; 13C NMR: 100 MHz; 19F NMR: 376 MHz) or Bruker BBO (1H NMR: 500 MHz) spectrometer, measured in the solvent indicated, with tetramethylsilane (TMS) as an internal standard. Coupling constants (J) are reported in hertz (Hz). The LC-HRMS analyses were performed by using electrospray ionisation in positive ion modus after separation by liquid chromatography (Nexera from Shimadzu). The elemental composition was derived from the averaged mass spectra acquired at the high resolution of about 30,000 with an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). The high-mass accuracy below 1 ppm was obtained by using a lock mass. GC spectra were measured on a HP-5890 GC with an FID detector, HPLC on an Agilent 1100 with a UV detector.

Groebke–Blackburn–Bienaymé Type Cyclisation; General Procedure

A reactor equipped with a Dean–Stark reflux condenser was charged with 2-aminopyrazine (1 equiv), aldehyde (1 equiv), PTSA (1.2 mol%), and toluene (0.5 m) under an atmosphere of nitrogen. The reaction mixture was heated to 110 °C for 16 h. After cooling the mixture to r.t., trimethyl orthoformate (2 equiv) and BF3·MeCN 1 m (4 mol%) were added. A freshly prepared solution of isocyanide (1.3 equiv) was then added dropwise and the reaction mixture was stirred at r.t. for 24 h. MeOH (about 6 equiv) was added and the mixture was stirred for another 10 min. The reaction mixture was concentrated under reduced pressure at 50 °C. The crude product was dissolved in a minimum amount of i-PrOH at reflux. Concentrated sulfuric acid (1.3 equiv) was added slowly to the solution. The precipitation mixture was slowly cooled to –10 °C. The precipitate was filtered, rinsed with cold i-PrOH (minimum amount) and dried under reduced pressure to furnish the desired product as a sulfate salt.


#

2-Phenyl-N-(p-tolyl)imidazo[1,2-a]pyrazin-3-amine (1a)

The corresponding sulfate salt was obtained as a dark-orange solid.

1H NMR (400 MHz, DMSO + D2O): δ = 9.46 (s, 1 H), 8.24 (d, J = 4.5 Hz, 1 H), 8.05 (d, J = 4.5 Hz, 1 H), 8.02 (d, J = 7.5 Hz, 2 H), 7.40–7.47 (m, 3 H), 6.96 (d, J = 7.8 Hz, 2 H), 6.52 (d, J = 7.5 Hz, 2 H), 2.15 (s, 3 H).

13C NMR (100 MHz, DMSO + D2O): δ = 142.2, 141.1, 138.4, 135.5, 131.1, 130.5, 130.1, 129.4, 129.2, 127.6, 124.7, 124.7, 118.8, 114.5, 20.5.

HR-LC MS: m/z [M + H]+ calcd for C19H17N4 +: 301.14477; found: 301.14482.


#

N-(2,3-Difluorophenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1b)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 1.33 g (85%).

1H NMR (400 MHz, DMSO + D2O): δ = 9.35 (s, 1 H), 8.28 (dd, J = 5.0, 1.3 Hz, 1 H), 8.00–8.05 (m, 3 H), 7.30 (t, J = 9.0 Hz, 2 H), 7.19 (q, J = 9.5 Hz, 1 H), 6.62 (ddd, J = 12.5, 6.8, 2.8 Hz, 1 H), 6.37–6.40 (m, 1 H).

13C NMR (100 MHz, DMSO): δ = 163.1 (d, J = 247.3 Hz), 150.6 (dd, J = 244.3, 12.4 Hz), 143.8 (dd, J = 236.2, 12.4 Hz), 141.7 (d, J = 7.3 Hz), 141.2, 139.8, 136.4, 129.8 (2C), 128.3, 125.5, 123.0, 118.9, 118.7 (d, J = 18.3 Hz), 116.4 (d, J = 21.2 Hz, 2C), 110.3, 103.4 (d, J = 21.3 Hz).

HR-LC MS: m/z [M + H]+ calcd for C18H12F3N4 +: 341.10086; found: 341.10108.


#

N-(3-Fluorophenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1c)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 1.36 g (70%).

1H NMR (400 MHz, DMSO): δ = 10.93 (br, 2 H), 9.49 (d, J = 1.0 Hz, 1 H), 8.79 (s, 1 H), 8.32 (dd, J = 5.1, 1.2 Hz, 1 H), 8.06–8.09 (m, 1 H), 8.08 (dd, J = 9.3, 4.5 Hz, 2 H), 7.32 (t, J = 9.0 Hz, 2 H), 7.01 (t, J = 8.8 Hz, 2 H), 6.64 (dd, J = 8.9, 4.3 Hz, 1 H).

13C NMR (100 MHz, DMSO): δ = 163.0 (d, J = 247.2 Hz), 156.8 (d, J = 235.5 Hz), 141.3, 140.4, 139.5, 136.1, 129.8 (d, J = 8.8 Hz, 2C), 128.4, 125.2, 124.0, 118.8, 116.5 (d, J = 22.0 Hz, 2C), 116.4 (d, J = 21.3 Hz, 2C), 115.7 (d, J = 7.3 Hz, 2C).

HR-LC MS: m/z [M + H]+ calcd for C18H13F2N4 +: 323.11028; found: 323.11047.


#

N-(3-Fluorophenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1d)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 1.18 g (75%).

1H NMR (400 MHz, DMSO): δ = 10.36 (br, 2 H), 9.48 (d, J = 0.8 Hz, 1 H), 8.99 (s, 1 H), 8.33 (dd, J = 4.8, 0.8 Hz, 1 H), 8.06–8.10 (m, 3 H), 7.33 (t, J = 8.9 Hz, 2 H), 7.18 (dd, J = 15.1, 8.0 Hz, 1 H), 6.59 (td, J = 8.5, 2.1 Hz, 1 H), 6.41–6.47 (m, 2 H).

13C NMR (100 MHz, DMSO): δ = 163.8 (d, J = 242.0 Hz), 163.1 (d, J = 247.4 Hz), 146.3 (d, J = 10.8 Hz), 141.4, 139.8, 136.4, 131.7 (d, J = 10.0 Hz), 129.8 (d, J = 8.5 Hz, 2C), 128.2 (d, J = 3.1 Hz), 125.5, 122.9, 118.9, 116.5 (d, J = 21.6 Hz, 2C), 110.5, 106.5 (d, J = 21.6 Hz), 101.3 (d, J = 26.2 Hz).

HR-LC MS: m/z [M + H]+ calcd for C18H13F2N4 +: 323.11028; found: 323.11042.


#

N-(2-Fluorophenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1e)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 1.11 g (77%).

1H NMR (400 MHz, DMSO): δ = 10.84 (br, 2 H), 9.46 (d, J = 1.3 Hz, 1 H), 8.66 (s, 1 H), 8.41 (dd, J = 5.0, 1.3 Hz, 1 H), 8.05–8.08 (m, 3 H), 7.32 (t, J = 8.9 Hz, 2 H), 7.25 (ddd, J = 11.9, 8.0, 1.5 Hz, 1 H), 6.78–6.88 (m, 2 H), 6.28 (td, J = 8.3, 1.5 Hz, 1 H).

13C NMR (100 MHz, DMSO): δ = 163.1 (d, J = 247.2 Hz), 152.0 (d, J = 241.4 Hz), 141.9, 139.7, 136.3, 132.0 (d, J = 11.8 Hz), 129.7 (d, J = 8.8 Hz, 2C), 128.4, 125.5, 125.1, 122.9, 120.7, 119.0, 116.4 (d, J = 21.3 Hz, 2C), 116.3–116.5 (m), 115.2.

HR-LC MS: m/z [M + H]+ cald for C18H13F2N4 +: 323.11028; found: 323.11051.


#

N-(4-Nitrophenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1f)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 1.40 g (78%).

1H NMR (400 MHz, DMSO + D2O): δ = 9.42 (d, J = 1.1 Hz, 1 H), 8.32 (dd, J = 5.0, 1.1 Hz, 1 H), 8.02–8.07 (m, 5 H), 7.31 (t, J = 8.9 Hz, 2 H), 6.75 (d, J = 8.7 Hz, 2 H).

13C NMR (100 MHz, DMSO): δ = 163.1 (d, J = 247.2 Hz), 151.0 (2C), 141.4, 140.7, 140.1, 136.9, 129.7 (d, 2C, J = 8.4 Hz), 128.3, 126.6 (2C), 126.4, 120.9, 118.8, 116.5 (d, J = 22.4 Hz, 2C), 114.0.

HR-LC MS: m/z [M + H]+ calcd for C18H13FN4O2 +: 350.10478; found: 350.10483.


#

N-(4-Chlorophenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1g)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 1.29 g (68%).

1H NMR (400 MHz, DMSO): δ = 10.45 (br, 2 H), 9.46 (s, 1 H), 8.89 (s, 1 H, HSO4-), 8.30 (d, J = 5.0 Hz, 1 H), 8.05–8.08 (m, 3 H), 7.33 (t, J = 8.9 Hz, 2 H), 7.19 (d, J = 8.9 Hz, 2 H), 6.62 (d, J = 8.9 Hz, 2 H).

13C NMR (100 MHz, DMSO): δ = 163.1 (d, J = 247.2 Hz), 143.1, 141.5, 139.6, 136.2, 129.8 (4C), 128.3, 125.2, 123.7, 123.3, 119.0, 116.5 (d, J = 21.2 Hz, 2C), 116.0 (2C).

HR-LC MS: m/z [M + H]+ cald for C18H13ClFN4 +: 339.08073; found: 339.08092.


#

N-(p-Methylphenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1h)

The corresponding sulfate was obtained as a yellow-brown solid.

Yield: 1.11 g (62%).

1H NMR (400 MHz, DMSO): δ = 9.48 (s, 1 H), 9.05 (br, 2 H), 8.65 (s, 1 H, HSO4-), 8.26 (d, J = 5.0 Hz, 1 H), 8.09 (dd, J = 8.5, 5.5 Hz, 2 H), 8.07 (d, J = 5.0 Hz, 1 H), 7.32 (t, J = 8.5 Hz, 2 H), 6.98 (d, J = 8.2 Hz, 2 H), 6.53 (d, J = 8.2 Hz, 2 H), 2.17 (s, 3 H, CH3).

13C NMR (100 MHz, 100 MHz, DMSO): δ = 163.1 (d, J = 247.2 Hz), 141.6, 141.3, 139.0, 135.9, 130.5 (2C), 129.8 (d, J = 8.1 Hz, 2C), 129.0, 128.3, 124.6 (2C), 119.0, 116.4 (d, J = 22.0 Hz, 2C), 114.6 (2C), 20.6 (CH3).

HR-LC MS: m/z [M + H]+ cald for C19H16FN4 +: 319.13535; found: 319.13543.


#

N-(4-Methoxyphenyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1i)

The corresponding sulfate salt was obtained as an ochre solid.

Yield: 1.41 g (90%).

1H NMR (400 MHz, DMSO): δ = 9.47 (s, 1 H), 9.47 (br, 2 H), 8.57 (br s, 1 H), 8.26 (d, J = 6.0 Hz, 1 H), 8.03–8.07 (m, 3 H), 7.31 (t, J = 8.9 Hz, 2 H), 6.77 (d, J = 9.0 Hz, 2 H), 6.58 (d, J = 9.0 Hz, 2 H), 3.64 (s, 3 H, CH3).

13C NMR (100 MHz, DMSO): δ = 163.1 (d, J = 247.3 Hz), 153.8, 141.7, 138.4, 136.9, 135.6, 129.9 (d, J = 8.1 Hz, 2C), 128.2, 125.6, 123.9, 119.0, 116.4 (d, J = 22.0 Hz, 2C), 116.0 (2C), 115.4 (2C), 55.7 (CH3).

HR-LC MS: m/z [M + H]+ cald for C19H16FN4O+: 335.13027; found: 335.13043.


#

N-(Cyclohexyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1j)

The corresponding sulfate salt was obtained as a yellow solid.

Yield: 0.89 g (66%).

1H NMR (400 MHz, DMSO + D2O): δ = 9.09 (s, 1 H), 8.53 (d, J = 5.3 Hz, 1 H), 8.03 (dd, J = 8.5, 5.5 Hz, 2 H), 7.86 (d, J = 5.3 Hz, 1 H), 7.33 (t, J = 8.9 Hz, 2 H), 2.91–2.96 (m, 1 H), 1.68 (d, J = 10.5 Hz, 2 H), 1.57 (d, J = 12.0 Hz, 2 H), 1.41 (m, 1 H), 1.21–1.26 (m, 2 H), 0.92–1.07 (m, 3 H).

13C NMR (100 MHz, DMSO): δ = 162.99 (d, J = 247.2 Hz), 140.1, 135.8, 133.8, 133.0, 130.2 (d, J = 8.1 Hz, 2C), 129.2, 121.5, 118.2, 116.3 (d, J = 22.0 Hz, 2C), 56.3, 34.0, 25.5, 25.1.

HR-LC MS: m/z [M + H]+ cald for C18H20FN4 +: 311.16665; found: 311.16677.


#

N-(Isopropyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1k)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 0.80 g (87%).

1H NMR (400 MHz, DMSO): δ = 10.0–9.0 (2 H, br s), 9.34 (s, 1 H), 8.75 (d, J = 5.3 Hz, 1 H), 8.10 (dd, J = 8.7, 5.7 Hz, 2 H), 8.02 (d, J = 5.5 Hz, 1 H), 7.39 (t, J = 8.9 Hz, 2 H), 3.38 (sept, J = 6.3 Hz, 1 H), 1.09 (d, J = 6.3 Hz, 6 H).

13C NMR (100 MHz, DMSO): δ = 163.0 (d, J = 247.2 Hz), 140.2, 135.9, 133.8, 133.3, 130.1 (d, J = 8.1 Hz, 2C), 129.2, 121.5, 118.2, 116.4 (d, J = 22.0 Hz, 2C), 49.0, 23.6 (2C).

HR-LC MS: m/z [M + H]+ calcd for C15H16FN4 +: 271.13535; found: 271.13531.


#

N-(p-Toluenesulfonylmethyl)-2-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-amine (1l)

Purification of the crude was conducted differently. The crude material was suspended in EtOAc and stirred at 50 °C for a few hours. The suspension was then cooled to 0 °C and filtered off. The solid was washed with EtOAc and 1l was obtained as a pale-brown solid.

Yield: 0.40 g (70%).

1H NMR (400 MHz, DMSO): δ = 8.77 (s, 1 H), 8.09 (d, J = 3.8 Hz, 1 H), 7.86–7.89 (m, 2 H), 7.76 (d, J = 4.8 Hz, 1 H), 7.41 (d, J = 8.0 Hz, 2 H), 7.18 (t, J = 8.8 Hz, 2 H), 7.11 (d, J = 8.0 Hz, 2 H), 6.46 (t, J = 6.9 Hz, 1 H), 4.54 (d, J = 7.0 Hz, 2 H), 2.22 (s, 3 H, CH3).

13C NMR (100 MHz, DMSO): δ = 162.4 (d, J = 245.8 Hz), 144.7, 142.7, 136.2, 136.0, 135.0, 129.9 (3C), 129.6 (d, J = 8.1 Hz, 2C), 128.8, 128.1 (2C), 125.2, 117.2, 116.0 (d, J = 21.3 Hz, 2C), 68.7, 21.5.

HR-LC MS: m/z [M + H]+ calcd for C20H18FN4O2 +: 397.11290; found: 397.11288.


#

N-(3,4-Difluorophenyl)-2-(4-chlorophenyl)imidazo[1,2-a]pyrazin-3-amine (1n)

The corresponding sulfate salt was obtained as a yellow solid.

Yield: 0.93 g (86%).

1H NMR (400 MHz, DMSO + D2O): δ = 9.32 (s, 1 H), 8.27 (d, J = 4.6 Hz, 1 H), 7.96–8.01 (m, 3 H), 7.49 (d, J = 8.5 Hz, 2 H), 7.16 (dt, J = 9.8, 9.2 Hz, 1 H), 6.57–6.61 (m, 1 H), 6.35–6.38 (m, 1 H).

13C NMR (100 MHz, DMSO): δ = 150.5 (J = 244.3, 13.9 Hz, dd), 143.9 (J = 237.0, 13.2 Hz, dd), 141.6 (br), 141.0, 140.1, 136.5, 134.5, 130.7, 129.5 (2C), 129.2 (2C), 125.4, 123.3, 119.0, 118.7 (d, J = 17.6 Hz), 110.3, 103.4 (d, J = 20.5 Hz).

HR-LC MS: m/z [M + H]+ calcd for C18H12ClF2N4 +: 357.07131; found: 357.07132.


#

N-(3,4-Difluorophenyl)-2-phenylimidazo[1,2-a]pyrazin-3-amine (1o)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 0.91 g (95%).

1H NMR (400 MHz, DMSO + D2O): δ = 9.32 (d, J = 1.3 Hz, 1 H), 8.29 (dd, J = 5.0, 1.3 Hz, 1 H), 8.03 (d, J = 5.0 Hz, 1 H), 7.95 (d, J = 8.3 Hz, 2 H),), 7.39–7.45 (m, 3 H), 7.16 (dt, J = 10.3, 9.0 Hz, 1 H), 6.56–6.62 (m, 1 H), 6.38–6.40 (m, 1 H).

13C NMR (100 MHz, DMSO): δ = 150.5 (dd, J = 244.3, 13.9 Hz), 143.8 (dd, J = 237.0, 12.5 Hz), 141.8 (d, J = 9.5 Hz), 141.7 (d, J = 8.1 Hz), 139.5, 136.2, 131.3, 130.0, 129.5 (2C), 127.6 (2C), 125.5, 123.4, 119.0, 118.7 (d, J = 17.6 Hz), 110.4, 103.3 (d, J = 21.3 Hz).

HR-LC MS: m/z [M + H]+ calcd for C18H13F2N4 +: 323.11028; found: 323.11030.


#

N-(3,4-Difluorophenyl)-2-(4-methylphenyl)imidazo[1,2-a]pyra­zin-3-amine (1p)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 0.99 g (84%).

1H NMR (400 MHz, DMSO + D2O): δ = 9.33 (d, J = 1.0 Hz, 1 H), 8.31 (dd, J = 4.9, 1.1 Hz, 1 H), 8.05 (d, J = 5.0 Hz, 1 H), 7.85 (d, J = 8 Hz, 2 H), 7.25 (d, J = 8.0 Hz, 2 H), 7.19–7.12 (m, 1 H,), 6.62–6.57 (m, 1 H), 6.38–6.40 (m, 1 H), 2.28 (s, 3 H).

13C NMR (100 MHz, DMSO): δ = 150.1 (dd, J = 243.6, 13.4 Hz), 143.5 (dd, J = 236.5, 12.9 Hz), 141.4, 141.2 (d, J = 8.5 Hz), 139.9, 138.9, 135.9, 130.1 (2C), 128.2, 127.5 (2C), 125.5, 123.2, 119.0, 118.7 (d, J = 18.3 Hz), 110.4, 103.4 (d, J = 20.6 Hz), 21.4.

HR-LC MS: m/z [M + H]+ calcd for C19H15F2N4 +: 337.12593; found: 337.12604.


#

N-(3,4-Difluorophenyl)-2-(4-methoxylphenyl)imidazo[1,2-a]pyrazin-3-amine (1q)

The corresponding sulfate salt was obtained as a mustard-yellow solid.

Yield: 1.01 g (82%).

1H NMR (400 MHz, DMSO + D2O): δ = 9.34 (d, J = 1.0 Hz, 1 H), 8.31 (dd, J = 5.0, 1.3 Hz, 1 H), 8.06 (d, J = 5.0 Hz, 1 H), 7.94 (d, J = 9.1 Hz, 2 H), 7.19 (dt, J = 10.3, 9.1 Hz, 1 H), 7.02 (d, J = 9.1 Hz, 2 H), 6.59–6.64 (m, 1 H), 6.40–6.42 (m, 1 H), 3.76 (s, 3 H).

13C NMR (100 MHz, DMSO): δ = 160.8, 150.5 (dd, J = 243.5, 13.2 Hz), 143.8 (dd, J = 236.3, 13.2 Hz), 141.8 (br, 2C), 138.6, 135.9, 129.1 (2C), 125.7, 123.3, 122.6, 118.8, 118.7 (d, J = 19.0 Hz), 115.0 (2C), 110.3, 103.3 (d, J = 21.3 Hz), 55.8.

HR-LC MS: m/z [M + H]+ calcd for C19H15F2N4O+: 353.12084; found: 353.12097.


#

N-(3,4-Difluorophenyl)-5-methyl-2-phenylimidazo[1,2-a]pyridin-3-amine (7)

2-Amino-6-methylpyridine was used instead of 2-aminopyrazine.

Purification of the crude material was conducted differently. The crude material was suspended in TBME and stirred at r.t. for a few hours. The suspension was then cool to 0 °C and filtered off. The solid was washed with TBME and 7 was obtained as a white solid.

Yield: 1.01 g (67%).

1H NMR (400 MHz, DMSO): δ = 8.31 (s, 1 H), 8.01 (d, J = 8.5 Hz, 2 H), 7.48 (d, J = 9.0 Hz, 1 H), 7.38 (t, J = 7.8 Hz, 2 H), 7.13 –7.31 (m, 3 H), 6.66 (d, J = 6.8 Hz, 1 H), 6.43 (br s, 1 H), 6.19 (br s, 1 H), 2.65 (s, 3 H).

13C NMR (100 MHz, DMSO): δ = 150.7 (dd, J = 243.5, 13.9 Hz), 146.0 (dd, J = 8.5 Hz), 143.9, 142.9 (dd, J = 234.2, 13.1 Hz), 139.3, 136.5, 133.6, 128.9 (2C), 128.2, 127.1 (2C), 126.4, 119.6, 118.8 (d, J = 17.7 Hz), 115.6, 114.2, 108.8, 101.8 (d, J = 20.0 Hz), 18.8.

19F NMR (377 MHz, DMSO): δ = –137.1 (d, J = 23.2 Hz), –152.6 (d, J = 23.0 Hz).

HR-LC MS: m/z [M + H]+ calcd for C20H16F2N3 +: 336.1312; found: 336.1310.


#
#

Acknowledgment

The skilful work and support of our technical staff (J. Keusch, F. Navarro) is gratefully acknowledged. We thank C. Guenat for measuring the HR-LC/MS spectra and the structure elucidation group of NIBR for their generous support and help.

Supporting Information

  • References

  • 1 New address: E. Durantie, Adolphe Merkle Institute, BioNanomaterial, Chemin des Verdiers 4, 1700 Fribourg, Switzerland.
  • 2 Groebke K, Weber L, Mehlin F. Synlett 1998; 661
  • 3 Blackburn C, Guan B, Fleming P, Shiosaki K, Tsai S. Tetrahedron Lett. 1998; 39: 3635
  • 4 Bienaymé H, Bouzid K. Angew. Chem. Int. Ed. 1998; 37: 2234
    • 5a Zhang W, Lu Y, Scott PJ. H In Solid-Phase Organic Syntheses . Scott PJ. H. John Wiley & Sons, Inc; Hoboken: 2012: 51-57
    • 5b Ramesha AB, Raghavendra GM, Nandeesh KN, Rangappa KS, Mantelingu K. Tetrahedron Lett. 2013; 54: 95
    • 5c Guchhait SK, Chaudhary V, Madaan C. Org. Biomol. Chem. 2012; 10: 9271
    • 5d Shukla NM, Salunke DB, Yoo E, Mutz CA, Balakrishna R, David SA. Bioorg. Med. Chem. 2012; 20: 5850
    • 5e Hieke M, Rödl CB, Wisniewska JM, laBuscató E, Stark H, Schubert-Zsilavecz M, Steinhilber D, Hofmann B, Proschak E. Bioorg. Med. Chem. Lett. 2012; 22: 1969
    • 5f Tyagi V, Khan S, Bajpai V, Gauniyal HM, Kumar B, Chauhan PM. S. J. Org. Chem. 2012; 77: 1414
    • 5g Baviskar AT, Madaan C, Preet R, Mohapatra P, Jain V, Agarwal A, Guchhait SK, Kundu CN, Banerjee UC, Bharatam PV. J. Med. Chem. 2011; 54: 5013
    • 5h Burchak ON, Mugherli L, Ostuni M, Lacapère JJ, Balakirev MY. J. Am. Chem. Soc. 2011; 133: 10058
    • 5i Guasconi M, Lu X, Massarotti A, Caldarelli A, Ciraolo E, Tron GC, Hirsch E, Sorba G, Pirali T. Org. Biomol. Chem. 2011; 9: 4144
    • 5j Akritopoulou-Zanze I, Wakefield BD, Gasiecki A, Kalvin D, Johnson EF, Kovar P, Djuric SW. Bioorg. Med. Chem. Lett. 2011; 21: 1480
    • 5k Buckmelter AJ, Ren L, Laird ER, Rast B, Miknis G, Wenglowsky S, Schlachter S, Welch M, Tarlton E, Grina J, Lyssikatos J, Brandhuber BJ, Morales T, Randolph N, Vigers G, Martinson M, Callejo M. Bioorg. Med. Chem. Lett. 2011; 21: 1248
    • 5l Guchhait SK, Madaan C. Org. Biomol. Chem. 2010; 8: 3631
    • 5m Al-Tel TH, Al-Qawasmeh RA, Voelter W. Eur. J. Org. Chem. 2010; 5586
    • 5n Guchhait S, Madaan C. Synlett 2009; 628
    • 5o Krasavin M, Tsirulnikov S, Nikulnikov M, Sandulenko Y, Bukhryakov K. Tetrahedron Lett. 2008; 49: 7318
    • 5p Kercher T, Rao C, Bencsik JR, Josey JA. J. Comb. Chem. 2007; 9: 1177
    • 5q Shaabani A, Soleimani E, Maleki A. Monatsh. Chem. 2007; 138: 73
    • 5r Masquelin T, Bui H, Brickley B, Stephenson G, Schwerkoske J, Hulme C. Tetrahedron Lett. 2006; 47: 2989
    • 5s Parchinsky VZ, Shuvalova O, Ushakova O, Kravchenko DV, Krasavin M. Tetrahedron Lett. 2006; 47: 947
    • 5t Lu Y, Zhang W. QSAR Comb. Sci. 2004; 23: 827
    • 5u Ireland SM, Tye H, Whittaker M. Tetrahedron Lett. 2003; 44: 4369
    • 5v Blackburn C, Guan B. Tetrahedron Lett. 2000; 41: 1495
    • 5w Varma RS, Kumar D. Tetrahedron Lett. 1999; 40: 7665
    • 6a Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C, Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA, Glynne R, Tully DC, Chatterjee AK. J. Med. Chem. 2012; 55: 4244
    • 6b Wu T, Nagle A, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Goh A, Lakshminarayana SB, Wu J, Ang HQ, Zeng P, Kang ML, Tan W, Tan M, Ye N, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Hollenbeck T, Tuntland T, Isbell J, Fischli C, Brun R, Rottmann M, Dartois V, Keller T, Diagana T, Winzeler E, Glynne R, Tully DC, Chatterjee AK. J. Med. Chem. 2011; 54: 5116
  • 7 Adib M, Mahdavi M, Noghani MA, Mirzaei P. Tetrahedron Lett. 2007; 48: 7263
  • 8 Dömling A, Ugi I. Angew. Chem. Int. Ed. 2000; 39: 3168
  • 9 Chan AK.-W, Wong KM.-C, Yam VW.-W. J. Am. Chem. Soc. 2015; 137: 6920
  • 10 Zakrzewski J, Huras B, Kiełczewska A. Synthesis 2016; 48: 85
  • 11 Lygin AV, de Meijere A. Org. Lett. 2009; 11: 389
  • 12 Polisar JG, Norton JR. Tetrahedron 2012; 68: 10236
  • 13 Wang J, Rosingana M, Discordia RP, Soundararajan N, Polniaszek R. Synlett 2001; 1485

  • References

  • 1 New address: E. Durantie, Adolphe Merkle Institute, BioNanomaterial, Chemin des Verdiers 4, 1700 Fribourg, Switzerland.
  • 2 Groebke K, Weber L, Mehlin F. Synlett 1998; 661
  • 3 Blackburn C, Guan B, Fleming P, Shiosaki K, Tsai S. Tetrahedron Lett. 1998; 39: 3635
  • 4 Bienaymé H, Bouzid K. Angew. Chem. Int. Ed. 1998; 37: 2234
    • 5a Zhang W, Lu Y, Scott PJ. H In Solid-Phase Organic Syntheses . Scott PJ. H. John Wiley & Sons, Inc; Hoboken: 2012: 51-57
    • 5b Ramesha AB, Raghavendra GM, Nandeesh KN, Rangappa KS, Mantelingu K. Tetrahedron Lett. 2013; 54: 95
    • 5c Guchhait SK, Chaudhary V, Madaan C. Org. Biomol. Chem. 2012; 10: 9271
    • 5d Shukla NM, Salunke DB, Yoo E, Mutz CA, Balakrishna R, David SA. Bioorg. Med. Chem. 2012; 20: 5850
    • 5e Hieke M, Rödl CB, Wisniewska JM, laBuscató E, Stark H, Schubert-Zsilavecz M, Steinhilber D, Hofmann B, Proschak E. Bioorg. Med. Chem. Lett. 2012; 22: 1969
    • 5f Tyagi V, Khan S, Bajpai V, Gauniyal HM, Kumar B, Chauhan PM. S. J. Org. Chem. 2012; 77: 1414
    • 5g Baviskar AT, Madaan C, Preet R, Mohapatra P, Jain V, Agarwal A, Guchhait SK, Kundu CN, Banerjee UC, Bharatam PV. J. Med. Chem. 2011; 54: 5013
    • 5h Burchak ON, Mugherli L, Ostuni M, Lacapère JJ, Balakirev MY. J. Am. Chem. Soc. 2011; 133: 10058
    • 5i Guasconi M, Lu X, Massarotti A, Caldarelli A, Ciraolo E, Tron GC, Hirsch E, Sorba G, Pirali T. Org. Biomol. Chem. 2011; 9: 4144
    • 5j Akritopoulou-Zanze I, Wakefield BD, Gasiecki A, Kalvin D, Johnson EF, Kovar P, Djuric SW. Bioorg. Med. Chem. Lett. 2011; 21: 1480
    • 5k Buckmelter AJ, Ren L, Laird ER, Rast B, Miknis G, Wenglowsky S, Schlachter S, Welch M, Tarlton E, Grina J, Lyssikatos J, Brandhuber BJ, Morales T, Randolph N, Vigers G, Martinson M, Callejo M. Bioorg. Med. Chem. Lett. 2011; 21: 1248
    • 5l Guchhait SK, Madaan C. Org. Biomol. Chem. 2010; 8: 3631
    • 5m Al-Tel TH, Al-Qawasmeh RA, Voelter W. Eur. J. Org. Chem. 2010; 5586
    • 5n Guchhait S, Madaan C. Synlett 2009; 628
    • 5o Krasavin M, Tsirulnikov S, Nikulnikov M, Sandulenko Y, Bukhryakov K. Tetrahedron Lett. 2008; 49: 7318
    • 5p Kercher T, Rao C, Bencsik JR, Josey JA. J. Comb. Chem. 2007; 9: 1177
    • 5q Shaabani A, Soleimani E, Maleki A. Monatsh. Chem. 2007; 138: 73
    • 5r Masquelin T, Bui H, Brickley B, Stephenson G, Schwerkoske J, Hulme C. Tetrahedron Lett. 2006; 47: 2989
    • 5s Parchinsky VZ, Shuvalova O, Ushakova O, Kravchenko DV, Krasavin M. Tetrahedron Lett. 2006; 47: 947
    • 5t Lu Y, Zhang W. QSAR Comb. Sci. 2004; 23: 827
    • 5u Ireland SM, Tye H, Whittaker M. Tetrahedron Lett. 2003; 44: 4369
    • 5v Blackburn C, Guan B. Tetrahedron Lett. 2000; 41: 1495
    • 5w Varma RS, Kumar D. Tetrahedron Lett. 1999; 40: 7665
    • 6a Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C, Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA, Glynne R, Tully DC, Chatterjee AK. J. Med. Chem. 2012; 55: 4244
    • 6b Wu T, Nagle A, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Goh A, Lakshminarayana SB, Wu J, Ang HQ, Zeng P, Kang ML, Tan W, Tan M, Ye N, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Hollenbeck T, Tuntland T, Isbell J, Fischli C, Brun R, Rottmann M, Dartois V, Keller T, Diagana T, Winzeler E, Glynne R, Tully DC, Chatterjee AK. J. Med. Chem. 2011; 54: 5116
  • 7 Adib M, Mahdavi M, Noghani MA, Mirzaei P. Tetrahedron Lett. 2007; 48: 7263
  • 8 Dömling A, Ugi I. Angew. Chem. Int. Ed. 2000; 39: 3168
  • 9 Chan AK.-W, Wong KM.-C, Yam VW.-W. J. Am. Chem. Soc. 2015; 137: 6920
  • 10 Zakrzewski J, Huras B, Kiełczewska A. Synthesis 2016; 48: 85
  • 11 Lygin AV, de Meijere A. Org. Lett. 2009; 11: 389
  • 12 Polisar JG, Norton JR. Tetrahedron 2012; 68: 10236
  • 13 Wang J, Rosingana M, Discordia RP, Soundararajan N, Polniaszek R. Synlett 2001; 1485

Zoom Image
Scheme 1 Toward a one-pot process. Reagents and conditions: 2 (1 equiv), 3a (1 equiv), 4a (1 equiv), PTSA (1.2 mol%), BF3·MeCN (4 mol%), r.t., CH2Cl2.
Zoom Image
Scheme 2 Preparation of isocyanide
Zoom Image
Scheme 3 A scalable one-pot process. Isolated yield of the corresponding salt.
Zoom Image
Scheme 4 Proposed mechanism
Zoom Image
Scheme 5 Preliminary result for the formation of 3-aminoimidazo[1,2-a]pyridine. Reagents and conditions: 1. 6 (1 equiv), 3b (1 equiv), PTSA (1 mol%), toluene, reflux, 16 h; 2. 4b (1.3 equiv), BF3 _MeCN (5 mol%), trimethyl orthoformate (2 equiv), CH2Cl2, r.t., 24 h.